US2020009202A1PendingUtilityA1

Bacterial composition and its use

64
Assignee: DUPONT NUTRITION BIOSCI APSPriority: Dec 5, 2002Filed: Mar 11, 2019Published: Jan 9, 2020
Est. expiryDec 5, 2022(expired)· nominal 20-yr term from priority
Inventors:Véronique DenninGregory LeyerAnnick MercenierSophie NuttenBruno Pot
A61P 37/08A61P 37/04A61P 37/02A61P 37/00A61P 29/00A61P 1/00A61K 35/747C12N 1/20A61K 35/745C12R 1/01C12R 1/25C12R 1/23C12R 1/225C12R 2001/23C12R 2001/25C12R 2001/225C12R 2001/01C12N 1/205
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The subject or the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.

Claims

exact text as granted — not AI-modified
1 - 21 . (canceled) 
     
     
         22 . A method for preventing or reducing inflammatory bowel syndrome, maintaining the homeostasis of the immune system, or reducing the allergenicity of a human or animal in need thereof, wherein the method comprises administering to the human or animal an effective amount of a bacterial composition comprising  Bifidobacterium bifidum  PTA-4801. 
     
     
         23 . A method according to  claim 22 , wherein the method is a method for preventing or reducing inflammatory bowel syndrome in the human or animal. 
     
     
         24 . A method according to  claim 22 , wherein the method is a method for maintaining the homeostasis of the immune system of the human or animal. 
     
     
         25 . A method according to  claim 22 , wherein the method is a method for reducing the allergenicity of the human or animal. 
     
     
         26 . A method according to  claim 22 , wherein the  Bifidobacterium bifidum  PTA-4801 is the only probiotic bacteria in the bacterial composition. 
     
     
         27 . A method according to  claim 22 , wherein the bacterial composition further comprises at least one additional strain selected from the group consisting of  Lactobacillus acidophilus  PTA-4797 , Lactobacillus plantarum  PTA-4799,  Lactobacillus salivarius  PTA-4800 , Lactobacillus paracasei  PTA-4798 and  Bifidobacterium lactis  PTA-4802. 
     
     
         28 . A method according to  claim 22 , wherein the bacterial composition further comprises at least two additional strains selected from the group consisting of  Lactobacillus acidophilus  PTA-4797,  Lactobacillus plantarum  PTA-4799,  Lactobacillus salivarius  PTA-4800 , Lactobacillus paracasei  PTA-4798 and  Bifidobacterium lactis  PTA-4802. 
     
     
         29 . A method according to  claim 22 , wherein the bacterial composition comprises from 10 6  to 10 11  CFU of bacteria/g of composition. 
     
     
         30 . A method according to  claim 22 , wherein the bacterial composition comprises from 10 8  to 10 11  CFU of bacteria/g of composition. 
     
     
         31 . A method according to  claim 22 , wherein the method comprises administering to a human in need thereof an effective amount of a bacterial composition comprising  Bifidobacterium bifidum  PTA-4801.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.